Spots Global Cancer Trial Database for eribulin mesylate
Every month we try and update this database with for eribulin mesylate cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| This is a Phase 1 Study of Eribulin Mesylate in Pediatric Participants With Recurrent or Refractory Solid Tumors (Excluding [Central Nervous System] CNS), Including Lymphomas | NCT02171260 | Pediatrics Solid Tumors | Eribulin Mesyla... | 6 Months - 17 Years | Eisai Inc. | |
| Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors | NCT02014337 | Breast Cancer Ovarian Epithel... Sarcoma Non-small Cell ... Carcinoma, Tran... Prostate Cancer Prostatic Neopl... | Mifepristone an... | 18 Years - | Corcept Therapeutics | |
| Halaven Post-Marketing Surveillance (PMS) | NCT02441764 | Breast Cancer | - | Eisai Inc. | ||
| An Open-Label, Multi-Center, Expanded Access Program With Eribulin for the Treatment of Advanced Breast Cancer Refractory | NCT01240421 | Metastatic Brea... | Eribulin Mesyla... | 18 Years - | Eisai Inc. | |
| Eribulin Mesylate in Treating Patients With Advanced or Recurrent Cervical Cancer | NCT01676818 | Recurrent Cervi... Stage IIIA Cerv... Stage IIIB Cerv... Stage IVA Cervi... Stage IVB Cervi... | eribulin mesyla... | 18 Years - | University of Southern California | |
| Eribulin Mesylate as Second-Line Therapy for Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer Patients | NCT00383760 | Adenocarcinoma ... Pancreatic Canc... Recurrent Pancr... Stage II Pancre... Stage III Pancr... Stage IV Pancre... | eribulin mesyla... | 18 Years - | National Cancer Institute (NCI) | |
| Dose Dense Doxorubucin and Cyclophosphamide Followed by Eribulin Mesylate for the Adjuvant Treatment of Early Stage Breast Cancer | NCT01328249 | HER2-normal | eribulin mesyla... | 18 Years - 100 Years | Eisai Inc. | |
| Halaven Patient Registry (Metastatic Breast Cancer, MBC) | NCT03245112 | Metastatic Brea... Advanced Breast... | Eribulin Mesyla... | 24 Years - 85 Years | Chang Gung Memorial Hospital | |
| A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast Cancer | NCT03583944 | Breast Neoplasm... | Eribulin Mesyla... | 18 Years - | Eisai Inc. | |
| Eribulin Mesylate in Treating Patients With Previously Treated Metastatic Breast Cancer | NCT01908101 | Recurrent Breas... Stage IV Breast... | Eribulin Mesyla... Laboratory Biom... | 18 Years - | University of Washington | |
| A Confirmation Study of Eribulin in Combination With Capecitabine | NCT01323530 | Metastatic Brea... | Eribulin mesyla... Capecitabine | 18 Years - | Eisai Inc. | |
| Testing the Addition of Copanlisib to Eribulin for the Treatment of Advanced-Stage Triple Negative Breast Cancer | NCT04345913 | Anatomic Stage ... Anatomic Stage ... Metastatic Trip... Unresectable Tr... | Biopsy Biospecimen Col... Computed Tomogr... Copanlisib Hydr... Eribulin Mesyla... Magnetic Resona... | 18 Years - | National Cancer Institute (NCI) | |
| Post-marketing Surveillance for the Clinical Safety and Effectiveness of Eribulin Mesylate in Patients With Inoperable or Recurrent Breast Cancer (Study HAL01S) | NCT01463891 | Inoperable or R... | Eribulin Mesyla... | 18 Years - | Eisai Inc. | |
| Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients With Bladder Cancer That is Advanced or Cannot Be Removed by Surgery | NCT02178241 | Metastatic Uret... Metastatic Uret... Stage III Bladd... Stage III Urete... Stage III Ureth... Stage IV Bladde... Stage IV Ureter... Stage IV Urethr... Ureter Urotheli... Urethral Urothe... | Eribulin Mesyla... Gemcitabine Hyd... | 18 Years - | National Cancer Institute (NCI) | |
| Eribulin Mesylate and Gemcitabine Hydrochloride in Treating Patients With Metastatic Solid Tumors or Solid Tumors That Cannot be Removed by Surgery | NCT00410553 | Adult Solid Neo... Recurrent Ovari... Recurrent Uteri... Stage III Ovari... Stage III Uteri... Stage IV Ovaria... Stage IV Uterin... | Eribulin Mesyla... Gemcitabine Hyd... | 18 Years - | National Cancer Institute (NCI) | |
| A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast Cancer | NCT03583944 | Breast Neoplasm... | Eribulin Mesyla... | 18 Years - | Eisai Inc. | |
| S0618 E7389 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer | NCT00337129 | Head and Neck C... | eribulin mesyla... | 18 Years - | National Cancer Institute (NCI) | |
| Eribulin [Halaven] Use For the Treatment of Advanced Breast Cancer | NCT02790320 | Metastatic Brea... | 18 Years - | Eisai Inc. | ||
| Eribulin Mesylate Phase IV Clinical Trial in Korean Patients With Metastatic or Locally Advanced Breast Cancer | NCT01961544 | Breast Neoplasm... Breast Cancer | Eribulin mesyla... | 20 Years - | Eisai Inc. | |
| Post-marketing Surveillance for the Clinical Safety and Effectiveness of Eribulin Mesylate in Patients With Inoperable or Recurrent Breast Cancer (Study HAL01S) | NCT01463891 | Inoperable or R... | Eribulin Mesyla... | 18 Years - | Eisai Inc. | |
| Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors | NCT02014337 | Breast Cancer Ovarian Epithel... Sarcoma Non-small Cell ... Carcinoma, Tran... Prostate Cancer Prostatic Neopl... | Mifepristone an... | 18 Years - | Corcept Therapeutics | |
| Grapiprant and Eribulin for the Treatment of Metastatic Inflammatory Breast Cancer | NCT05041101 | Breast Inflamma... Recurrent Breas... Stage IV Breast... | Eribulin Mesyla... Grapiprant | 18 Years - | M.D. Anderson Cancer Center | |
| Second Line ERIbulin Followed by CApecitabine or the Reverse Sequence in HER2-negative Metastatic Breast Cancer Patients | NCT05833919 | Metastatic Brea... | Eribulin Mesyla... Capecitabine | 18 Years - | Consorzio Oncotech | |
| Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer | NCT01439282 | Estrogen Recept... Breast Cancer | eribulin mesyla... capecitabine | 18 Years - | Eisai Inc. | |
| Rebastinib Plus Antitubulin Therapy With Paclitaxel or Eribulin in Metastatic Breast Cancer | NCT02824575 | Breast Cancer Breast Adenocar... Human Epidermal... Recurrent Breas... Stage IV Breast... | Rebastinib Paclitaxel Eribulin Mesyla... | 18 Years - | Montefiore Medical Center | |
| Eribulin Mesylate in Treating Patients With Recurrent or Refractory Osteosarcoma | NCT02097238 | Recurrent Osteo... | Eribulin Mesyla... Pharmacological... | 12 Years - 49 Years | National Cancer Institute (NCI) | |
| A Study to Investigate the Efficacy and Safety of Eribulin in Korean Breast Cancer Participants | NCT03437083 | Locally Advance... | Eribulin mesyla... | - | Eisai Inc. | |
| Grapiprant and Eribulin for the Treatment of Metastatic Inflammatory Breast Cancer | NCT05041101 | Breast Inflamma... Recurrent Breas... Stage IV Breast... | Eribulin Mesyla... Grapiprant | 18 Years - | M.D. Anderson Cancer Center | |
| Maintenance Treatment With Eribulin Mesylate Versus Observation in Triple Negative Breast Cancer Patients | NCT04502680 | Triple Negative... | Eribulin Mesyla... | 18 Years - | The First Affiliated Hospital with Nanjing Medical University | |
| E7389 in Treating Patients With Recurrent or Progressive Stage IIIB or Stage IV Non-Small Cell Lung Cancer | NCT00400829 | Recurrent Non-s... Stage IIIB Non-... Stage IV Non-sm... | eribulin mesyla... | 18 Years - | National Cancer Institute (NCI) | |
| PAINTER: Polymorphism And INcidence of Toxicity in ERibulin Treatment | NCT02864030 | Metastatic Brea... Toxicity Neurotoxicity Drug Toxicity Adverse Drug Ev... | ERIBULIN MESYLA... | 18 Years - | Oncologia Medica dell'Ospedale Fatebenefratelli | |
| Study of Eribulin in Children With Cancer to Determine Safety | NCT02082626 | Pediatric Cance... Solid Tumors Lymphoma | Eribulin mesyla... | - 20 Years | University of Oklahoma | |
| Eribulin With Trastuzumab as First-line Therapy for Locally Recurrent or Metastatic HER2 Positive Breast Cancer | NCT01269346 | Breast Cancer | Eribulin Mesyla... | 18 Years - | Eisai Inc. | |
| Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction | NCT00365157 | Advanced Urothe... Locally Advance... Metastatic Urot... Recurrent Uroth... Stage III Bladd... Stage IV Bladde... Unresectable Ur... | Eribulin Mesyla... Laboratory Biom... Pharmacological... | 18 Years - | National Cancer Institute (NCI) | |
| Rebastinib Plus Antitubulin Therapy With Paclitaxel or Eribulin in Metastatic Breast Cancer | NCT02824575 | Breast Cancer Breast Adenocar... Human Epidermal... Recurrent Breas... Stage IV Breast... | Rebastinib Paclitaxel Eribulin Mesyla... | 18 Years - | Montefiore Medical Center | |
| An Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Previously Treated Subjects With Advanced or Metastatic Soft Tissue Sarcoma (Study E7389-J081-217) | NCT01458249 | Soft Tissue Sar... | eribulin mesyla... | 20 Years - | Eisai Inc. | |
| Treatment of Brain Metastases From Breast Cancer With Eribulin Mesylate | NCT02581839 | Metastatic Brea... Brain Metastase... | Eribulin Mesyla... MRI Pre-Medication:... Pre-Medication:... | 18 Years - | Case Comprehensive Cancer Center | |
| A Study Combining Eribulin Mesylate With Avelumab in Cisplatin Ineligible Metastatic Urothelial Cell Cancer Patients | NCT03502681 | Metastatic Urot... | Eribulin Mesyla... Avelumab | 18 Years - | Big Ten Cancer Research Consortium | |
| To Assess the Effect of Rifampicin on the Pharmacokinetics of Eribulin Mesylate in Participants With Advanced Solid Tumors | NCT03002493 | Tumor | Eribulin mesyla... Eribulin mesyla... Rifampicin | 18 Years - | Eisai Inc. | |
| A Study on Safety and Efficacy in Patients With Soft Tissue Sarcomas | NCT03058406 | Sarcoma, Soft T... | Eribulin mesyla... | - | Eisai Inc. | |
| EPOCH: Eribulin and Pembrolizumab in Ovarian/Uterine Carcinosarcoma | NCT05619913 | Ovarian Carcino... Uterine Carcino... | Eribulin Mesyla... Pembrolizumab | 18 Years - | Australia New Zealand Gynaecological Oncology Group | |
| Treatment of Brain Metastases From Breast Cancer With Eribulin Mesylate | NCT02581839 | Metastatic Brea... Brain Metastase... | Eribulin Mesyla... MRI Pre-Medication:... Pre-Medication:... | 18 Years - | Case Comprehensive Cancer Center | |
| A Study to Investigate the Efficacy and Safety of Eribulin in Korean Breast Cancer Participants | NCT03437083 | Locally Advance... | Eribulin mesyla... | - | Eisai Inc. | |
| Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients With Bladder Cancer That is Advanced or Cannot Be Removed by Surgery | NCT02178241 | Metastatic Uret... Metastatic Uret... Stage III Bladd... Stage III Urete... Stage III Ureth... Stage IV Bladde... Stage IV Ureter... Stage IV Urethr... Ureter Urotheli... Urethral Urothe... | Eribulin Mesyla... Gemcitabine Hyd... | 18 Years - | National Cancer Institute (NCI) | |
| Eribulin and Radiation Therapy in Treating Patients With Retroperitoneal Liposarcoma That Can Be Removed by Surgery | NCT03361436 | Liposarcoma Malignant Abdom... Malignant Retro... Malignant Scrot... Malignant Solid... Malignant Sperm... | Eribulin Mesyla... Intensity-Modul... Laboratory Biom... Quality-of-Life... Questionnaire A... Therapeutic Con... | 12 Years - | OHSU Knight Cancer Institute | |
| Neuropharmacokinetics of Eribulin Mesylate in Treating Patients With Primary or Metastatic Brain Tumors | NCT02338037 | Metastatic Mali... Primary Brain T... | Therapeutic Con... Biopsy Eribulin Mesyla... Microdialysis Pharmacological... | 18 Years - | City of Hope Medical Center | |
| Eribulin Mesylate in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy | NCT00337077 | Adenocarcinoma ... Hormone-refract... Recurrent Prost... Stage IV Prosta... | eribulin mesyla... | 18 Years - | National Cancer Institute (NCI) | |
| Eribulin Combined With Anlotinib in Metastatic HER2 Negative Breast Cancer | NCT04624711 | HER2-negative B... | Eribulin Mesyla... Anlotinib hydro... | 18 Years - 80 Years | The First Affiliated Hospital with Nanjing Medical University | |
| A Study on Safety and Efficacy in Patients With Soft Tissue Sarcomas | NCT03058406 | Sarcoma, Soft T... | Eribulin mesyla... | - | Eisai Inc. | |
| Eribulin Mesylate in Treating Patients With Recurrent Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer | NCT00334893 | Fallopian Tube ... Primary Periton... Recurrent Ovari... | eribulin mesyla... | 18 Years - | National Cancer Institute (NCI) | |
| Eribulin Mesylate Administered in Combination With Pemetrexed Versus Pemetrexed Alone as Second Line Therapy in Patients With Stage IIIB or IV Nonsquamous Non Small Cell Lung Cancer | NCT01126736 | Non Small Cell ... | eribulin mesyla... pemetrexed Eribulin mesyla... | 18 Years - | Eisai Inc. | |
| Eribulin Mesylate in Treating Patients With Advanced or Recurrent Cervical Cancer | NCT01676818 | Recurrent Cervi... Stage IIIA Cerv... Stage IIIB Cerv... Stage IVA Cervi... Stage IVB Cervi... | eribulin mesyla... | 18 Years - | University of Southern California | |
| A Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer | NCT01268150 | Locally Recurre... Metastatic Brea... | Eribulin mesyla... | 18 Years - | Eisai Inc. | |
| Compassionate Use of Eribulin for the Treatment of Advanced Breast Cancer Refractory to All Other Marketed Therapies | NCT01142661 | Breast Cancer | Eribulin Mesyla... | 18 Years - | Eisai Inc. | |
| A Randomized Phase II Study Of Eribulin Mesylate With or Without Pembrolizumab For Metastatic Hormone Receptor Positive Breast Cancer | NCT03051659 | Breast Cancer | Eribulin Mesyla... Pembrolizumab | 18 Years - | Dana-Farber Cancer Institute | |
| A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast Cancer | NCT03583944 | Breast Neoplasm... | Eribulin Mesyla... | 18 Years - | Eisai Inc. | |
| Carboplatin and Eribulin Mesylate in Triple Negative Breast Cancer Patients | NCT01372579 | Estrogen Recept... HER2-negative B... Male Breast Can... Progesterone Re... Stage IA Breast... Stage IB Breast... Stage II Breast... Stage IIIA Brea... Stage IIIB Brea... Stage IIIC Brea... Triple-negative... | eribulin mesyla... carboplatin biopsy | 18 Years - | Northwestern University | |
| S0618 E7389 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer | NCT00337129 | Head and Neck C... | eribulin mesyla... | 18 Years - | National Cancer Institute (NCI) | |
| Maintenance Treatment With Eribulin Mesylate Versus Observation in Triple Negative Breast Cancer Patients | NCT04502680 | Triple Negative... | Eribulin Mesyla... | 18 Years - | The First Affiliated Hospital with Nanjing Medical University | |
| E7389 in Treating Patients With Recurrent or Progressive Stage IIIB or Stage IV Non-Small Cell Lung Cancer | NCT00400829 | Recurrent Non-s... Stage IIIB Non-... Stage IV Non-sm... | eribulin mesyla... | 18 Years - | National Cancer Institute (NCI) | |
| M7824 and Eribulin Mesylate in Treating Patients With Metastatic Triple Negative Breast Cancer | NCT03579472 | Anatomic Stage ... Metastatic Trip... Prognostic Stag... | Bintrafusp Alfa Eribulin Mesyla... | 18 Years - | M.D. Anderson Cancer Center | |
| Eribulin Mesylate in Treating Patients With Previously Treated Metastatic Breast Cancer | NCT01908101 | Recurrent Breas... Stage IV Breast... | Eribulin Mesyla... Laboratory Biom... | 18 Years - | University of Washington | |
| An Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Previously Treated Subjects With Advanced or Metastatic Soft Tissue Sarcoma (Study E7389-J081-217) | NCT01458249 | Soft Tissue Sar... | eribulin mesyla... | 20 Years - | Eisai Inc. | |
| A Study Combining Eribulin Mesylate With Avelumab in Cisplatin Ineligible Metastatic Urothelial Cell Cancer Patients | NCT03502681 | Metastatic Urot... | Eribulin Mesyla... Avelumab | 18 Years - | Big Ten Cancer Research Consortium | |
| Eribulin With or Without Trastuzumab-biosimilar in Patients With HER2-overexpressed Recurrent or Stage IV Breast Cancer | NCT05530057 | Advanced Breast... | Eribulin Mesyla... Eribulin Mesyla... | 18 Years - | Seoul National University Hospital | |
| Eribulin Combined With Anlotinib in Metastatic HER2 Negative Breast Cancer | NCT04624711 | HER2-negative B... | Eribulin Mesyla... Anlotinib hydro... | 18 Years - 80 Years | The First Affiliated Hospital with Nanjing Medical University | |
| Testing the Addition of Copanlisib to Eribulin for the Treatment of Advanced-Stage Triple Negative Breast Cancer | NCT04345913 | Anatomic Stage ... Anatomic Stage ... Metastatic Trip... Unresectable Tr... | Biopsy Biospecimen Col... Computed Tomogr... Copanlisib Hydr... Eribulin Mesyla... Magnetic Resona... | 18 Years - | National Cancer Institute (NCI) | |
| Safety and Efficacy of Eribullin or Eribulin Combined With Anlotinib in Metastatic Breast Cancer | NCT05206656 | Metastatic Brea... | Eribulin Mesyla... Anlotinib | 18 Years - 70 Years | Hunan Cancer Hospital | |
| Eribulin Mesylate in Treating Patients With Recurrent Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer | NCT00334893 | Fallopian Tube ... Primary Periton... Recurrent Ovari... | eribulin mesyla... | 18 Years - | National Cancer Institute (NCI) | |
| Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer | NCT03237780 | Locally Advance... Locally Advance... Locally Advance... Locally Advance... Metastatic Blad... Metastatic Rena... Metastatic Uret... Metastatic Uret... Recurrent Bladd... Recurrent Renal... Recurrent Urete... Recurrent Ureth... Stage III Bladd... Stage III Renal... Stage III Urete... Stage III Ureth... Stage IV Bladde... Stage IV Renal ... Stage IV Ureter... Stage IV Urethr... Unresectable Bl... Unresectable Re... Unresectable Ur... Unresectable Ur... | Atezolizumab Biopsy Biospecimen Col... Computed Tomogr... Eribulin Mesyla... | 18 Years - | National Cancer Institute (NCI) | |
| Grapiprant and Eribulin for the Treatment of Metastatic Inflammatory Breast Cancer | NCT05041101 | Breast Inflamma... Recurrent Breas... Stage IV Breast... | Eribulin Mesyla... Grapiprant | 18 Years - | M.D. Anderson Cancer Center | |
| Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer | NCT03237780 | Locally Advance... Locally Advance... Locally Advance... Locally Advance... Metastatic Blad... Metastatic Rena... Metastatic Uret... Metastatic Uret... Recurrent Bladd... Recurrent Renal... Recurrent Urete... Recurrent Ureth... Stage III Bladd... Stage III Renal... Stage III Urete... Stage III Ureth... Stage IV Bladde... Stage IV Renal ... Stage IV Ureter... Stage IV Urethr... Unresectable Bl... Unresectable Re... Unresectable Ur... Unresectable Ur... | Atezolizumab Biopsy Biospecimen Col... Computed Tomogr... Eribulin Mesyla... | 18 Years - | National Cancer Institute (NCI) | |
| Post-Marketing Surveillance Study of Eribulin on the Status and Factors for the Development of Peripheral Neuropathy in Japan. | NCT02371174 | Breast Cancer HER2-negative B... | - | Eisai Inc. | ||
| Eribulin Mesylate Phase IV Clinical Trial in Korean Patients With Metastatic or Locally Advanced Breast Cancer | NCT01961544 | Breast Neoplasm... Breast Cancer | Eribulin mesyla... | 20 Years - | Eisai Inc. | |
| Eribulin Mesylate in Treating Patients With Recurrent or Refractory Osteosarcoma | NCT02097238 | Recurrent Osteo... | Eribulin Mesyla... Pharmacological... | 12 Years - 49 Years | National Cancer Institute (NCI) | |
| A Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer | NCT01268150 | Locally Recurre... Metastatic Brea... | Eribulin mesyla... | 18 Years - | Eisai Inc. | |
| Eribulin Mesylate Administered in Combination With Pemetrexed Versus Pemetrexed Alone as Second Line Therapy in Patients With Stage IIIB or IV Nonsquamous Non Small Cell Lung Cancer | NCT01126736 | Non Small Cell ... | eribulin mesyla... pemetrexed Eribulin mesyla... | 18 Years - | Eisai Inc. | |
| To Assess the Effect of Rifampicin on the Pharmacokinetics of Eribulin Mesylate in Participants With Advanced Solid Tumors | NCT03002493 | Tumor | Eribulin mesyla... Eribulin mesyla... Rifampicin | 18 Years - | Eisai Inc. | |
| Eribulin Mesylate in Treating Patients With Previously Treated Metastatic Breast Cancer | NCT01908101 | Recurrent Breas... Stage IV Breast... | Eribulin Mesyla... Laboratory Biom... | 18 Years - | University of Washington | |
| Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer | NCT04579224 | Metastatic Blad... Metastatic Rena... Metastatic Uret... Metastatic Uret... Metastatic Urot... Refractory Blad... Refractory Rena... Refractory Uret... Refractory Uret... Refractory Urot... Stage IV Bladde... Stage IV Renal ... Stage IV Renal ... Stage IV Ureter... Stage IV Urethr... Stage IVA Bladd... Stage IVB Bladd... | Biospecimen Col... Bone Scan Computed Tomogr... Docetaxel Eribulin Mesyla... Gemcitabine Hyd... Magnetic Resona... Paclitaxel Sacituzumab Gov... | 18 Years - | National Cancer Institute (NCI) |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
